Denis Furling

Denis Furling

Auto-generated profile, based on publicly available information

Denis Furling

Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2011 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CFCharlotte Fugier
Charlotte Fugier
AKArnaud F Klein
Arnaud F Klein
CHCaroline Hammer
Caroline Hammer
SVStéphane Vassilopoulos
Stéphane Vassilopoulos
Ylva IvarssonYlva Ivarsson
Ylva Ivarsson
NCNicolas Charlet-Berguerand
Nicolas Charlet-Berguerand

19 June 2011 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
FRFrédérique Rau
Frédérique Rau
FFFernande Freyermuth
Fernande Freyermuth
CFCharlotte Fugier
Charlotte Fugier
JVJean-Philippe Villemin
Jean-Philippe Villemin
MFMarie-Christine Fischer
Marie-Christine Fischer
NCNicolas Charlet-Berguerand
Nicolas Charlet-Berguerand

18 August 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SMSusan A. M. Mulders
Susan A. M. Mulders
WBWalther J. A. A. van Den Broek
Walther J. A. A. van Den Broek
TWThurman M. Wheeler
Thurman M. Wheeler
HCHuib J. E. Croes
Huib J. E. Croes
PKPetra van Kuik-Romeijn
Petra van Kuik-Romeijn
DWDerick G. Wansink
Derick G. Wansink
Myotonic dystrophy type 1 (DM1) is caused by toxicity of an expanded, noncoding (CUG)n tract in DM protein kinase (DMPK) transcripts. According to current evidence the long (CUG)n segment is involved in entrapment of muscleblind (Mbnl) proteins in ribonuclear aggregates and stabilized expression of CUG binding protein 1 (CUGBP1), causing aberrant premRNA splicing and associated pathogenesis in DM1 patients. Here, we report on the use of antisense oligonucleotides (AONs) in a therapeutic strategy for reversal of RNA-gain-of-function toxicity. Using a previously undescribed mouse DM1 myoblast−myotube cell model and DM1 patient cells as screening tools, we have identified a fully 2′-O-methyl-phosphorothioate-modified (CAG)7 AON that silences mutant DMPK RNA expression and reduces the number of ribonuclear aggregates in a selective and (CUG)n-length-dependent manner. Direct administration of this AON in muscle of DM1 mouse models in vivo caused a significant reduction in the level of toxic (CUG)n RNA and a normalizing effect on aberrant premRNA splicing. Our data demonstrate proof of principle for therapeutic use of simple sequence AONs in DM1 and potentially other unstable microsatellite diseases.

11 April 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
FFFernande Freyermuth
Fernande Freyermuth
FRFrédérique Rau
Frédérique Rau
YKYosuke Kokunai
Yosuke Kokunai
TLThomas Linke
Thomas Linke
CSChantal Sellier
Chantal Sellier
NCNicolas Charlet-Berguerand
Nicolas Charlet-Berguerand
Myotonic dystrophy (DM) is caused by the expression of mutant RNAs containing expanded CUG repeats that sequester muscleblind-like (MBNL) proteins, leading to alternative splicing changes. Cardiac alterations, characterized by conduction delays and arrhythmia, are the second most common cause of death in DM. Using RNA sequencing, here we identify novel splicing alterations in DM heart samples, including a switch from adult exon 6B towards fetal exon 6A in the cardiac sodium channel, SCN5A. We find that MBNL1 regulates alternative splicing of SCN5A mRNA and that the splicing variant of SCN5A produced in DM presents a reduced excitability compared with the control adult isoform. Importantly, reproducing splicing alteration of Scn5a in mice is sufficient to promote heart arrhythmia and cardiac-conduction delay, two predominant features of myotonic dystrophy. In conclusion, misregulation of the alternative splicing of SCN5A may contribute to a subset of the cardiac dysfunctions observed in myotonic dystrophy.

12 December 2016 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
SRSuzanne G Rzuczek
Suzanne G Rzuczek
LCLesley A Colgan
Lesley A Colgan
YNYoshio Nakai
Yoshio Nakai
MCMichael D Cameron
Michael D Cameron
DFDenis Furling
Denis Furling
MDMatthew D Disney
Matthew D Disney

1 December 2012 in Journal of Proteomics
Verified
Journal Article
Closed access
MBMarie-Catherine Le Bihan
Marie-Catherine Le Bihan
ABAnne Bigot
Anne Bigot
SJSøren Skov Jensen
Søren Skov Jensen
JDJayne L. Dennis
Jayne L. Dennis
ARAdelina Rogowska-Wrzesinska
Adelina Rogowska-Wrzesinska
Gillian Butler-BrowneGillian Butler-Browne
Gillian Butler-Browne